Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A major meta-analysis finds SGLT2 inhibitors consistently boost hemoglobin and hematocrit levels across diverse patient populations. Analyzing 85 randomized trials with over 70,000 patients, researchers found meaningful increases in red blood cell production markers — pointing to a real effect on iron metabolism, not just fluid loss. The findings suggest these drugs could play a meaningful role in managing chronic anemia.
SGLT2 inhibitors — already celebrated for their heart and kidney benefits — may have another trick up their sleeve: boosting red blood cell levels. A landmark systematic review and meta-analysis presented at the American Society of Nephrology Kidney Week and published in JAMA found that these drugs consistently raised hemoglobin and hematocrit across more than 70,000 patients with CKD, heart failure, type 2 diabetes, and cardiovascular disease.
Researchers say the effect goes beyond simple fluid loss. Alongside rising hemoglobin and hematocrit, patients on SGLT2 inhibitors showed higher erythropoietin levels and lower ferritin and transferrin saturation — a pattern suggesting the drugs actively stimulate red blood cell production and alter iron metabolism. Effects appeared dose- and duration-dependent, peaking around 48 weeks of treatment.
By the Numbers:
Why it matters: These findings open the door to using SGLT2 inhibitors as part of chronic anemia management — potentially reducing reliance on conventional anemia treatments. However, clinicians should watch for thromboembolic risk in patients who already have elevated baseline hemoglobin levels.
